Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst c

NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic w

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company de

Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks

Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy r

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst c

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical

https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/p

Cortigent is a leading developer of brain implant devices based on precision neurostimulation techno

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirs

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data sh

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:V

Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatm

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight lo

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for w

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurosti

Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to suppor

https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-ep

https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co

HC Wainwright & Co. analyst Yi Chen initiates coverage on Vivani Medical (NASDAQ:VANI) with a

https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.10) per share which beat the analyst c

Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 202

Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the In

Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tole

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the